Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NYSE | Common Stock
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers.
It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody.
In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF PartnersL. P. to support the discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -1.14 Decreased by -2.18 K% | -0.93 Decreased by -22.58% |
| Feb 19, 25 | -1.03 Increased by +4.63% | -1.20 Increased by +14.39% |
| Nov 6, 24 | -1.00 Decreased by -6.38% | -1.06 Increased by +5.66% |
| Aug 8, 24 | -1.02 Increased by +1.92% | -1.10 Increased by +7.27% |
| May 8, 24 | -0.05 Increased by +95.41% | -0.95 Increased by +94.74% |
| Feb 21, 24 | -1.08 Decreased by -16.13% | -1.02 Decreased by -5.88% |
| Nov 7, 23 | -0.94 Decreased by -4.44% | -1.13 Increased by +16.81% |
| Aug 7, 23 | -1.04 Decreased by -11.83% | -1.10 Increased by +5.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 28.00 M Decreased by -80.69% | -112.00 M Decreased by -2.70 K% | Decreased by -400.00% Decreased by -14.40 K% |
| Dec 31, 24 | 26.00 M Decreased by -16.13% | -94.00 M Decreased by -16.05% | Decreased by -361.54% Decreased by -38.37% |
| Sep 30, 24 | 48.00 M Increased by +50.00% | -92.00 M Decreased by -29.58% | Decreased by -191.67% Increased by +13.62% |
| Jun 30, 24 | 39.00 M Increased by +34.48% | -93.00 M Decreased by -24.00% | Decreased by -238.46% Increased by +7.79% |
| Mar 31, 24 | 145.00 M Increased by +480.00% | -4.00 M Increased by +95.00% | Decreased by -2.76% Increased by +99.14% |
| Dec 31, 23 | 31.00 M Increased by +8.89 K% | -81.00 M Decreased by -20.90% | Decreased by -261.29% Increased by +98.65% |
| Sep 30, 23 | 32.00 M Decreased by -4.71% | -71.00 M Decreased by -17.47% | Decreased by -221.88% Decreased by -23.27% |
| Jun 30, 23 | 29.00 M Increased by +8.37% | -75.00 M Decreased by -16.67% | Decreased by -258.62% Decreased by -7.66% |